ACTRN12608000289314终止不适用
Insulin sensitivity in response to an acute bout of resistance exercise in type 2 diabetic and non-diabetic individuals
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 40 Years 至 69 Years（—）
- 性别
- All
入选标准
- •Type 2 diabetes
- •Sedentary (less than 20 minutes of aerobic exercise twice a week)
排除标准
- •Recent coronary event
- •Uncontrolled hypertension
- •Significant orthopaedic disorder that would prevent them from completing resistance training
- •Chronic alcohol users
- •Any other medical condition that has resistance training as a contraindication
- •Taking insulin
- •Inability to understand English or follow instructions
研究者
相似试验
已完成
不适用
Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapyHypertension, type two diabetes, hypopituitarismNutritional, Metabolic, EndocrineHypertensionISRCTN84921696Royal Group Hospitals Trust (UK)45
进行中（未招募）
1 期
Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy. - Studies of insulin action in patients at increased vascular riskProtocol (a): Essential Hypertension Protocol (b): Hypertension in Type 2 Diabetes Protocol (c): PanhypopituitarismMedDRA version: 8.1 Level: LLT Classification code 10022489 Term: Insulin resistanceEUCTR2006-001562-16-GBRoyal Group of Hospitals Trust45
进行中（未招募）
不适用
Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic ControlDiabetes Type 2EUCTR2006-002354-30-DETakeda Pharma GmbH
进行中（未招募）
1 期
Treatment with Metformin and growth hormone in children with a low birth weightEUCTR2018-000584-85-DKRigshospitalet24
进行中（未招募）
不适用
Clinical study on the insulin sensitizing effect of multiple administration of Vition (Meditop) in healthy human volunteers (Pilot study)EUCTR2011-001859-36-HUMeditop Pharmaceuticals Co. Ltd.